References
- Parkin DM , BrayF, FerlayJ, PisaniP. Global cancer statistics, 2002. CA Cancer J. Clin.55(2) , 74–108 (2005).
- Adams L , RothMJ, AbnetCC et al. Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma. Cancer Prev. Res. (Phila.) 1(5) , 357–361 (2008).
- Toh Y , OkiE, OhgakiK et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int. J. Clin. Oncol. 15(2) , 135–144 (2010).
- Lin DC , DuXL, WangMR. Protein alterations in ESCC and clinical implications: a review. Dis. Esophagus22(1) , 9–20 (2009).
- Zhang XM , GuoMZ. The value of epigenetic markers in esophageal cancer. Front. Med. China4(4) , 378–384 (2010).
- El-Serag HB , GrahamDY, SatiaJA, RabeneckL. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am. J. Gastroenterol.100(6) , 1243–1250 (2005).
- Campbell NP , VillaflorVM. Neoadjuvant treatment of esophageal cancer. World J. Gastroenterol.16(30) , 3793–3803 (2010).
- Guo M , RenJ, BrockMV, HermanJG, CarrawayHE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics3(6) , 336–341 (2008).
- Kisiel W , SprecherCA, FosterDC. Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. Blood84(12) , 4384–4385 (1994).
- Rao CN , LiuYY, PeaveyCL, WoodleyDT. Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch. Biochem. Biophys.317(1) , 311–314 (1995).
- Tang Z , GengG, HuangQ et al. Expression of tissue factor pathway inhibitor 2 in human pancreatic carcinoma and its effect on tumor growth, invasion, and migration in vitro and in vivo. J. Surg. Res. 167(1) , 62–69 (2011).
- Gessler F , VossV, SeifertV, GerlachR, KogelD. Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Neurosci. Lett.497(1) , 49–54 (2011).
- Nobeyama Y , Okochi-TakadaE, FurutaJ et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int. J. Cancer 121(2) , 301–307 (2007).
- Wang S , XiaoX, ZhouX et al. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer10 , 617 (2010).
- Herman JG , GraffJR, MyohanenS, NelkinBD, BaylinSB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA93(18) , 9821–9826 (1996).
- Jia Y , YangY, LiuS, HermanJG, LuF, GuoM. SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics5(8) , 743–749 (2010).
- Griffiths EA , GoreSD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin. Hematol.45(1) , 23–30 (2008).
- Qin T , JelinekJ, SiJ, ShuJ, IssaJP. Mechanisms of resistance to 5-aza-2´-deoxycytidine in human cancer cell lines. Blood113(3) , 659–667 (2009).
- George J , GondiCS, DinhDH, GujratiM, RaoJS. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin. Cancer Res.13(12) , 3507–3517 (2007).
- Xu C , DengF, MaoZ et al. The interaction of the second Kunitz-type domain (KD2) of TFPI-2 with a novel interaction partner, prosaposin, mediates the inhibition of the invasion and migration of human fibrosarcoma cells. Biochem. J. 441(2) , 665–674 (2012).
- Ma S , ChanYP, KwanPS et al. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res. 71(2) , 583–592 (2011).
- Ollivier V , BentolilaS, ChabbatJ et al. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 91(8) , 2698–2703 (1998).
- Sprecher CA , KisielW, MathewesS et al. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc. Natl Acad. Sci. USA 91(8) , 3353–3357 (1994).
- Rao CN , LakkaSS, KinY et al. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin. Cancer Res. 7(3) , 570–576 (2001).
- Wu D , XiongL, WuS, JiangM, LianG, WangM. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer. Lung Cancer doi:10.1016/j.lungcan.2011.09.005 (2011) (Epub ahead of print).
- Wong CM , NgYL, LeeJM et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45(5) , 1129–1138 (2007).
- Guo H , LinY, ZhangH et al. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol. Biol. 8 , 110 (2007).
- Glockner SC , DhirM, YiJM et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69(11) , 4691–4699 (2009).